ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 308

Cross-Cultural Adaptation, Validation and Reliability Of The Brazilian Version Of The Psoriatic Arthritis Screening Evaluation Tool

Roberto Ranza1, Claudia G Schainberg2, Sueli Carneiro3, Gladys Martins4, Jose Joaquim Rodrigues5, Jamille Carneiro6, Ricardo Romiti7, Thiago B. M. Barros8, Ana Luiza Sampaio9, Amanda Pedreira9, Carolina Z Costa10, Rogerio MC Pinto11, M. Elaine Husni12 and Abrar A. Qureshi13, 1Universidade Federal de Uberlandia, Uberlandia MG, Brazil, 2Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 3Brazilian Registry of Spondyloarthritis, São Paulo, Brazil, 4Dermatologia Hospital Universitario Universidade de Brasilia, Brasilia, Brazil, 5Dermatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, 6Reumatologia, Universidade de Brasilia, Brasilia, Brazil, 7Dermatologia Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 8Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 9Dermatologia Hospital Universitário e Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 10Reumatologia, Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, 11Matematica, Matematica, Universidade Federal de Uberlandia, Uberlandia, Brazil, 12Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, 13Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: psoriatic arthritis and questionnaires

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Psoriatic Arthritis (PsA) remains an under–diagnosed disease among patients with psoriasis (PsO). Dermatologists are not routinely trained to detect musculoskeletal manifestations hence arthritis, enthesitis and spondylitis may be frequently missed at dermatology settings. The Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire is a patient reported outcome that may help dermatologists identify patients who may need a rheumatology referral. PASE is composed of 15 questions (2 subscales on symptoms and function), is reliable, generates a continuous score (15-75) higher in patients with PsA and is sensitive-to-change with disease severity and treatment. Purpose – to validate a Brazilian Portuguese version of the PASE (PASE-P)

Methods: PASE was translated into Portuguese with a wording adaptation of subscales titles and rating scale (disagree-agree substituted with false–true) to fit the cultural response style of Brazilian patients. A multicenter study was conducted in four university dermatology clinics, from January to March 2011. In each center, consecutive patients with a confirmed diagnosis of PsO responded to the PASE-P and were subsequently evaluated by a rheumatologist blind to the questionnaire. Based on clinical history and physical examination, patients were classified as: PsO only, PsO + osteoarthritis (OA) and/or chronic myofascial pain (CMP) syndrome, PsA (CASPAR criteria) ± OA and/or CMP.  Laboratory tests and x-Ray imaging were performed as clinically indicated by the rheumatologist. PASE-P was retested in a sub-sample after a mean time of 20 days (12-30)

Results: 465 PsO patients completed the study. Mean age was 48.8±15.7 yrs, 50% were females and PsO mean duration was 15.5±11.8yrs. The PASE-P distinguished participants with PsA (158) from non-PsA (307), with mean scores of 37.8 ±17.2 vs 22.7±11.5 (p<0.001), ROC AUC of 0.777 (95%CI: 0.732-0.823); the best cut point was 25, giving 0.728 sensitivity (SE) and 0.735 specificity (SP). Patients with PsA not on any systemic treatment (42) had higher scores (mean 47.5±14.1) and the best cutoff from non-PsA was 38, SE 0.786, SP 0.876 (AUC 0.908, 95%CI 0.868-0.948).  A subanalysis of PsA vs OA (66), showed scores of 37.8 vs 24.4±14.3 (p<0.001) and a cutoff of 22, 0.785 SE, 0.697 SP. (AUC 0.881, 95%CI 0.818-0.945). The internal consistency for PASE-P was high (Cronbach´s alfa 0.928) and the test-retest ICC was 0.974.

Conclusion: PASE-P is a newly translated tool that is reliable, sensitive and specific to screen for PsA in a population of Brazilian portuguese-speaking PsO patients seen in dermatology clinics


Disclosure:

R. Ranza,
None;

C. G. Schainberg,
None;

S. Carneiro,
None;

G. Martins,
None;

J. J. Rodrigues,
None;

J. Carneiro,
None;

R. Romiti,
None;

T. B. M. Barros,
None;

A. L. Sampaio,
None;

A. Pedreira,
None;

C. Z. Costa,
None;

R. M. Pinto,
None;

M. E. Husni,
None;

A. A. Qureshi,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cross-cultural-adaptation-validation-and-reliability-of-the-brazilian-version-of-the-psoriatic-arthritis-screening-evaluation-tool/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology